Keros Therapeutics (NASDAQ:KROS), founded in 2018 and headquartered in Boston, Massachusetts, is a clinical‐stage biopharmaceutical company focused on developing novel therapies for hematologic and rare diseases. The company’s strategic research centers on the pathophysiology of iron dysregulation, with a particular emphasis on disorders characterized by ineffective erythropoiesis and iron overload. Drawing on advances in peptide engineering, Keros has built a pipeline of injectable therapeutic candidates designed to modulate the hepcidin pathway and restore balanced iron homeostasis.
The lead candidate in Keros’s portfolio is rusfertide (PTG-300), a hepcidin mimetic currently in mid- to late‐stage clinical trials for conditions such as polycythemia vera and non‐transfusion‐dependent thalassemia. Early data have demonstrated the potential of rusfertide to reduce iron burden, mitigate phlebotomy requirements and improve key hematologic parameters. In addition to rusfertide, Keros is advancing several discovery‐stage programs aimed at addressing other rare and chronic hematologic indications, leveraging proprietary peptide scaffolds to achieve selective receptor engagement and durable therapeutic effects.
Operations extend across North America and Europe, with ongoing clinical studies conducted in multiple geographies to support future global regulatory submissions. Keros has established collaborative relationships with leading academic centers and patient advocacy groups to accelerate trial enrollment and ensure robust data generation. The company’s research facilities in Boston are complemented by external partnerships for manufacturing and nonclinical safety studies, facilitating seamless progression of candidates from laboratory to clinic.
Keros is guided by a leadership team with deep expertise in hematology, translational science and commercial strategy. Its executive management and board include veterans from industry innovators such as Alexion, Gilead and Relypsa, alongside academic opinion leaders in iron metabolism. This collective experience underpins Keros’s commitment to delivering transformative therapies for patients with unmet needs in the hematologic and rare disease landscape.
